Maris-Tech Ltd. — FY2022 Form 20-F
Reporting period: Fiscal year ended December 31, 2022; this is an annual report, not a standalone fourth-quarter filing. Maris-Tech is an Israel-based B2B designer and seller of miniature intelligent video, audio, and edge-AI systems for defense, homeland security, drones, robotics, and other markets. Financial statements are audited and prepared under U.S. GAAP, in U.S. dollars. The auditor gave an unqualified opinion on the financial statements.
Key financial results
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $2.505 million | $2.076 million |
| Gross profit | $783,000 | $969,000 |
| Gross margin | 31.3% | 46.7% |
| Research and development | $1.022 million | $706,000 |
| Sales and marketing | $604,000 | $241,000 |
| General and administrative | $2.841 million | $595,000 |
| Operating loss | $(3.684) million | $(573,000) |
| Net loss | $(3.688) million | $(824,000) |
| Operating cash flow | $(4.857) million | $(875,000) |
| Capital expenditures | $284,000 | $8,000 |
Financial position and liquidity
- At year-end, the balance sheet reported $222,000 cash and cash equivalents, $9.084 million in short-term bank deposits, and $12.254 million in current assets. Cash, cash equivalents, and restricted deposits together were $256,000; restricted deposits were $34,000.
- Working capital was $10.443 million, compared with a $995,000 deficit in 2021. Shareholders’ equity was $9.597 million, versus a $2.380 million capital deficit. Accumulated deficit was $8.193 million.
- Bank credit and bank loans were repaid during 2022; year-end bank debt was zero. The Company owed $1.088 million on interest-free loans from its CEO and another director. Operating lease liabilities totaled $586,000, including $144,000 current.
- Financing cash flow was $14.368 million, principally reflecting the February 2022 IPO. Investing cash outflow was $9.305 million, mainly due to placing IPO proceeds in short-term bank deposits.
- Management said available cash and short-term deposits were expected to fund current operations and obligations for the next 12 months. The Company nevertheless reported ongoing operating losses and negative operating cash flow.
Changes versus the prior year
- Revenue rose 21%, attributed to increased sales to existing and new customers, particularly in the United Kingdom and United States.
- Cost of revenue increased 56%, outpacing revenue growth; gross profit fell 19% and gross margin contracted to 31.3% from 46.7%. The Company cited higher component and production costs, COVID-era supply constraints, and a greater proportion of lower-margin distributor sales.
- Operating expenses increased substantially: R&D rose 45%, sales and marketing 151%, and general and administrative expense 377%. The latter included IPO/listing-related professional and director costs and recruitment of senior personnel.
- Net loss increased to $3.688 million from $824,000. Operating cash use increased to $4.857 million, partly reflecting higher receivables and inventory.
- The February 2022 IPO generated approximately $17.8 million gross proceeds and $15.1 million net proceeds. The Company used proceeds for R&D, sales and marketing, loan repayment, working capital, and general corporate purposes.
Outlook, commentary, and risks
- No formal revenue or earnings guidance is provided. Management expected losses to continue until products achieve commercial profitability and planned continued investment in product development and international sales, particularly in North America.
- Backlog was approximately $1.9 million on January 1, 2023 and $2.6 million on March 6, 2023. Management expected most of the latter to be delivered and recognized in 2023, with the remainder in 2024; backlog may be delayed, deferred, or canceled and is not a reliable guarantee of revenue.
- Notable orders included a $1.1 million December 2022 order for a Jade derivative from an existing defense customer, described as the Company’s largest to date; and a $660,000 January 2023 Onyx order from a new Australian customer, expected to be delivered in 2023. The filing also describes Opal orders and an agreement for up to $500,000 of additional purchases.
- Product-development plans included Jupiter XV, Jupiter Tactical, and Jupiter Payload launches targeted for Q3 2023; Saturn and Uranus-AI launches targeted for late 2023. These are management expectations, not assured launch dates or revenue commitments.
- Key business risks include continuing losses, dependence on additional funding for growth, customer acceptance and commercialization, concentrated customer revenue, competition, reliance on third-party component suppliers, manufacturing capacity, and uncertain backlog conversion. Component shortages have extended lead times and raised costs.
- Four customers accounted for approximately 75.8% of FY2022 revenue; the largest two represented 33.4% and 25.1%. Revenue by geography was led by Israel ($1.312 million), the United Kingdom ($836,000), and the United States ($302,000).
- Geopolitical and operating risks include instability in Israel and the Russia-Ukraine conflict, potential foreign-exchange effects, and regulatory and export-control requirements. The Company does not currently hedge foreign-currency exposure.
- Israeli Innovation Authority grants carry royalty and technology-transfer conditions. The filing reports approximately $285,000 of outstanding royalty obligations on certain earlier grants; moving related manufacturing or know-how outside Israel may require approval and could increase repayment obligations. A separate 2022 joint AI research grant was not subject to royalties.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end due to insufficient U.S. GAAP/SEC reporting personnel and inadequate segregation of duties. Remediation included hiring a CFO and chief accountant, seeking additional finance staff, and developing an accounting policy manual. The auditor did not attest to ICFR effectiveness.
- Nasdaq notified the Company of a minimum-bid-price deficiency in January 2023; the Company reported regaining compliance in March 2023. The Company also reported no material legal proceedings during the period and no dividends paid or expected in the foreseeable future.
Important facts for investors to verify
- Confirm the detailed financial statements and cash-flow reconciliation: MD&A describes $255,530 of cash and cash equivalents, while the balance sheet reports $221,961 cash and cash equivalents plus $33,569 restricted deposits.
- Assess whether cash and short-term deposits can support operations given the $4.857 million operating cash outflow, continuing losses, and planned R&D and market expansion.
- Track backlog conversion, delivery schedules, customer concentration, cancellations, and realized margins on large defense and distributor orders.
- Monitor remediation of the disclosed material weaknesses and whether subsequent filings report effective disclosure controls and internal control over financial reporting.
- Review the terms and dilution potential of outstanding warrants and options, the repayment schedule for the $1.088 million related-party loan, and any future equity financing.
- Check product-launch progress, supply availability and costs, and the approvals and obligations attached to IIA-supported technology and manufacturing.